THE
This comes after the EU's Medicines and Healthcare products Regulatory Agency (MHRA) pushed back its delivery of the dose to later in 2022 while it awaits approval.
The dose has been authorised to be given to people aged 18 or over with some groups, like people over 50, being entitled to some form of booster this autumn.
It was reported this week that there had been 50,414 cases in the last seven days, a 23.7 per cent drop from last week, according to government figures.
"What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve", MHRA chief executive
"This bivalent vaccine has an important role to play in protecting people in the
Medicines, agreed with the MHRA's decision, saying: "This novel bivalent vaccine represents the next step in the development of vaccines to combat the virus."
In the
(c) 2022 City A.M., source